Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 833

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 833
---
 $                 | 5 |     | $             | 5 |     | $           | — |     | $            | — |

The Company’s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. Note 5. Balance Sheet Components Property and equipment, net Property and equipment, net consists of the following (in thousands):

|                                |     | December 31, | 2024 |   |     |   | 2023 |   |
|:-------------------------------|:----|:-------------|-----:|:--|:----|:--|-----:|:--|
| Construction-in-progress       |     | $            |  689 |   |     | $ |  689 |   |
| Furniture                      |     |              |   17 |   |     |   |   17 |   |
| Computers and equipment        |     |              |    8 |   |     |   |    8 |   |
| Property and equipment, gross  |     |              |  714 |   |     |   |  714 |   |
| Less: Accumulated depreciation |     |              |  (25 | ) |     |   |  (25 | ) |
| Property and equipment, net    |     | $            |  689 |   |     | $ |  689 |   |

F-77

The Company recognized no depreciation expense for each of the years ended December 31, 2024 and 2023. Costs for long-lived assets not yet placed into service are capitalized as construction-in-progressand depreciated once placed into service. The Company assesses impairment on an annual basis. As of each of December 31, 2024 and 2023, there was no impairment identified on property and equipment. Accrued Expenses Accrued expenses consist of the following (in thousands):

|                                        |     | December 31, | 2024 |     |   | 2023 |
|:---------------------------------------|:----|:-------------|-----:|:----|:--|-----:|
| Accrued other                          |     | $            |   35 |     | $ |   37 |
| Accrued research and development costs |     |              |    — |     |